References
- Cancer Research UK, 2013. World cancer fact sheet. World cancer burden. 2012. Available from: http://publications.cancerresearchuk.org/downloads/product/CS_REPORT_WORLD.pdf
- Department of Health and Jane Ellison MP, 2013, Helping more people survive cancer. 25 March 2013
- Cancer Research UK. Worldwide cancer incidence statistics. 2014. Available from: www.cancerresearchuk.org/cancer-info/cancerstats/world/incidence/
- Jonsson B, Wilking N. A global comparison regarding patient access to cancer drugs. Ann Oncol 2007;18:Suppl 3
- Morgan S, Grootendorst P, Lexchin J, et al. The cost of drug development: a systematic review. Health Policy 2011;100:4-17
- Hay M, Thomas D, Craighead J, et al. Clinical development success rates for investigational drugs. Nat Biotechnol 2014;32:40-51
- Abrantes- Metz R, Adams C, Metz A. Pharmaceutical development phases: a duration analysis, bureau of economics, FTC. Working Paper number 274, Washington USA
- Daniel G, Caze A, Romine M, et al. Improving pharmaceutical innovation by building a more comprehensive database on drug development and use. Health Aff 2015;34:319-27
- Schulpher M. Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics 2008;26:799-806
- Clinicaltrials.gov. Available from: https://clinicaltrials.gov
- Dickson M, Gagnon J-P. The cost of new drug discovery and development. Discovery Medicine 2009. February 2015
- Drummond M, de Pouvourville G, Jones E, et al. A Comparative analysis of two contrasting european approaches for rewarding the value added by drugs for cancer: england versus france. Pharmacoeconomics 2014;32(5):509-20
- Persson U, Willis M, Odegaard K. A case study ofg the ex ante, value-based price and reimbursement of decision-making: TLV and rimonabant in Sweden. Eur J Health Econ 2010;11:195-203
- Mason A, Drummond M. Public funding of new cancer drugs: is NICE getting nastier? Eur J Cancer 2009;45:1188-92
- Mason A, Drummond M, Ramsey S, et al. Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric?. J Clin Oncol 2010;28(20):3234-8
- Raftery J. Multiple Sclerosis risk sharing scheme: a costly failure. BMJ 2010;340:1672